Verano Holdings (VRNO) Non-Current Deferred Tax Liability (2021 - 2026)
Verano Holdings (VRNO) reported Non-Current Deferred Tax Liability of $36.7 million for Q1 2026, down 49.73% year-over-year from $73.0 million in Q1 2025, and little changed quarter-over-quarter from $36.6 million in Q4 2025.
Verano Holdings (VRNO) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at $36.7 million in Q1 2026.
- Non-Current Deferred Tax Liability for Q1 2026 came in at $36.7 million, down 49.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $36.7 million (down 49.73% YoY), and the FY2025 annual result was $36.6 million, down 63.85% from the prior year.
- Non-Current Deferred Tax Liability steadied at $36.7 million in Q1 2026 per VRNO's latest filing, from $36.6 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $259.3 million in Q2 2022 and troughed at $2.7 million in Q1 2022.
- A 5-year average of $141.4 million and a median of $174.8 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2022 and 2025: Non-Current Deferred Tax Liability soared 26219.88% in 2022, then tumbled 63.85% in 2025.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $209.0 million in 2022, then slipped by 3.0% to $202.7 million in 2023, then slumped by 49.99% to $101.4 million in 2024, then plunged by 63.85% to $36.6 million in 2025, then gained by 0.11% to $36.7 million in 2026.
- Business Quant data shows VRNO's Non-Current Deferred Tax Liability at $36.7 million in Q1 2026, $36.6 million in Q4 2025, and $71.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Verano Holdings | - | - | 98.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.69 Mn |
| Mar 31, 2026 | 36.69 Mn |
| Dec 31, 2025 | 36.64 Mn |
| Dec 31, 2025 | 36.64 Mn |
| Sep 30, 2025 | 71.02 Mn |
| Sep 30, 2025 | 71.02 Mn |
| Jun 30, 2025 | 72.37 Mn |
| Jun 30, 2025 | 72.37 Mn |
| Mar 31, 2025 | 72.98 Mn |
| Mar 31, 2025 | 72.98 Mn |
| Dec 31, 2024 | 101.36 Mn |
| Dec 31, 2024 | 101.36 Mn |
| Sep 30, 2024 | 168.16 Mn |
| Sep 30, 2024 | 168.16 Mn |
| Jun 30, 2024 | 174.79 Mn |
| Jun 30, 2024 | 174.79 Mn |
| Mar 31, 2024 | 180.25 Mn |
| Mar 31, 2024 | 180.25 Mn |
| Dec 31, 2023 | 202.69 Mn |
| Dec 31, 2023 | 202.69 Mn |